Our Firm is representing Lipitor lawsuit plaintiffs in this proceeding, and we are pleased that discovery is continuing to progress.
New York, NY (PRWEB) April 29, 2015
The federal court overseeing thousands of Lipitor lawsuits (http://www.lipitorlawsuitcenter.com/) that allege the statin medication increases a patient’s risk for new-onset Type 2 diabetes had denied a defense motion to quash a marketing deposition sought by plaintiffs, though the Court has imposed certain limitations on the deposition. According to a Case Management Order issued on April 23rd in the U.S. District Court, District of South Carolina, the deposition is to take place on or before June 17, 2015. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502)
“Our Firm is representing Lipitor lawsuit plaintiffs in this proceeding, and we are pleased that discovery is continuing to progress. Depositions and other discovery activities will allow plaintiffs access to important information that may prove relevant to their claims,” says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing numerous victims of defective medical devices and drugs including Lipitor. The Firm continues to offer free and confidential Lipitor lawsuit evaluations to individuals who developed diabetes after use of this cholesterol statin.
According to court documents, Pfizer, Inc. is named a defendant in nearly 2,200 Lipitor lawsuits currently pending in the District of South Carolina, all of which accuse the company of failing to warn that use of its statin medication could increase the risk that a patient will develop Type 2 diabetes. The Court is currently preparing for the litigation’s bellwether trials, as jury selection in the first trial is set to begin on November 4, 2015. (Case No. 2:2015cv01132) A second case will likely go to trial in late 2015 or early 2016. (Case No. 2:2014cv01879)
Court records indicate that the Lipitor litigation began to grow after the U.S. Food & Drug Administration (FDA) announced in February 2012 that all statin labels would be updated to include information about their potentially harmful effects on blood glucose levels. Plaintiffs claim that the label modifications Pfizer made in the wake of this announcement were not sufficient to warn patients about the association between Lipitor and diabetes. They also allege that Pfizer was aware of data linking Lipitor to diabetes for years, but concealed this information in order to protect its lucrative market for the drug.
Lipitor patients who allegedly developed Type 2 diabetes due to its use may be entitled to compensation for medical bills, lost wages, pain and suffering, and other damages related to the disorder. To learn more about filing a Lipitor lawsuit, please visit Bernstein Liebhard LLP’s website. To arrange for a free case review, please call 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have ben able to recover more than $3 billion on behalf of our clients. The National Law Journal has recognized Bernstein Liebhard for twelve consecutive years as one of the top plaintiffs' firms in the country. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com